Powered by
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company developing novel treatments for endocrine diseases with significant unmet needs, reported a loss of $12 million or 65 cents per …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), the developer of new endocrine drugs, announced the promotion of Thomas Hoover to the newly created position of chief commercial officer. Hoover joined Millendo …
ANN ARBOR — Millendo Therapeutics Inc., the Ann Arbor pharma firm, announced an exclusive license agreement with the pharmaceutical giant AstraZeneca for the worldwide development and commercialization rights to AZD4901, …